The maverick practice of off-label prescribing - giving drugs for unapproved conditions/patients - is once again in the limelight. The US Food and Drug Administration (FDA) has issued a warning against using ‘atypical antipsychotics’ to treat...
The maverick practice of off-label prescribing - giving drugs for unapproved conditions/patients - is once again in the limelight. The US Food and Drug Administration (FDA) has issued a warning against using ‘atypical antipsychotics’ to treat...